Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Lymecycline may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Tetralysal belongs to a group of medicines called tetracycline antibiotics. The main use of Tetralysal is to treat acne. Acne appears as blackheads and whiteheads which people often refer to as pimples or spots. Tetralysal attacks the bacteria that are one of the main causes of acne. The name of these bacteria is propionibacterium acnes. This medicine can also be used to treat many other infections caused by bacteria. If you are not sure why you have been prescribed this medicine, talk to your doctor.
e Tetralysal Do not take Tetralysal if: you are to lymecycline or to other tetracycline antibiotics such as doxycycline or any of the other ingredients of this medicine (listed in section 6). An allergic reaction may include either a rash or itching you have ever had kidney disease you are pregnant, planning to become pregnant or are breast-feeding Tetralysal must not be given to children under 8 years of age. Tetralysal must not be taken at the same time as medicines which contain oral retinoids (these include some other medicines used to treat acne). Warnings and precautions Talk to your doctor or pharmacist before taking Tetralysal. Tell your doctor before taking Tetralysal if you have hepatic impairment or renal insufficiency (failure of liver and kidney function). suffer from systemic lupus erythematosus (an allergic condition that causes joint pain, skin rashes or fever) or Myasthenia Gravis (a disease that weakens the muscles). Overdosing might result in liver problems. You should avoid direct exposure to sunlight or artificial sunlight from sunbeds. If you experience skin discomfort then stop taking this medicine and seek advice from your doctor. Do not use this medicine if the expiry date has passed, expired Tetralysal can cause kidney disorder. As with other antibiotics, treatment with tetracycline can cause secondary bacterial or mycotic infections (fungal). There is in particular the possibility of resistant staphylococcal enterocolitis (inflammation of the small intestine and colon due to bacteria that are resistant to the therapeutic action of the drug). Should you undergo cycles of prolonged treatment with Tetralysal, your doctor will prescribe regular checks of blood composition and liver and kidney function. Take the medicine with adequate amounts of water to avoid irritation or ulceration of the esophagus. Children Tetralysal should not be used in children under 8 years because of the risk of permanent alterations of tooth and enamel discoloration. Other medicines and Tetralysal Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Tell your doctor if you are taking any of the following medicines: medicines to thin your blood e.g. warfarin diuretics (used to treat kidney disease, heart disease or high blood pressure)
Tetralysal Always take this medicine exactly as your doctor has told you. The correct dose will be shown on the label which your pharmacist has placed on the container. Check with your doctor or pharmacist if you are not sure. Please tear the aluminium strip carefully to remove capsule. –
–
–
Galderma
Printing Colors
Product code: P23873-l3 Product description: TETRALYSAL 300 Market: GBR Article: Leaflet Font size: 8 pt Flat size: 180×315 Fold size: 180×26,25 Pharmacode: 130 GRAPHIC DESIGNER: Guillaume
GALDE RMA
INDUSTRIALIZATION DEPARTMENT –
–
PMS 432U
NOTICE VERSO 180×315 PLAN n° MT.09.DRA.0352.R02.2 Adults and children over 12 years Acne The normal dose is one Tetralysal capsule once a day (300 mg/day), preferably in the morning. Tetralysal capsules should always be taken with a glass of water. How long you will have to take Tetralysal for will depend on how quickly your condition improves. For acne, this will normally be at least 8 weeks. Infections The normal dose is one Tetralysal capsule twice a day (600 mg/day). Your doctor may a lower or higher dose depending on the severity and type of infection. Ask your doctor if you are unsure. Tetralysal capsules should always be taken with a glass of water. Do not give Tetralysal to children below the age of 8, it could harm them. If you take more Tetralysal than you should If you, or anyone else, take too many Tetralysal capsules phone your doctor for advice or go to your nearest hospital so that medical staff are made aware of the problem. Don't forget to take the container with you. This could indicate how many capsules have been taken. If you forget to take Tetralysal Do not worry if you forget to take your Tetralysal at the right time. Take it when you remember and carry on as before unless it is time for the next dose. Do not double up the dose to make up for a forgotten capsule. You should never take more capsules than your doctor recommends. If you stop taking Tetralysal Acne responds slowly to antibiotics. It is important that you take all the Tetralysal that your doctor has prescribed for you. If you stop taking Tetralysal too soon, your acne or infection could get worse or come back. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
although not everybody gets them. Like all medicines, this medicine can cause side If you experience any of the following stop taking these tablets immediately and see a doctor:
–
–
headache
Not known: frequency cannot be estimated from the available data allergic (hypersensitivity) reaction causing swelling of the eyes, lips or tongue blistering or peeling of large areas of the skin ulcerations or lesions on the mouth, lips, genital or anal regions disturbances of eyesight*
–
–
–
dizziness vomiting (being sick) yellowing of the skin or eyes inflammation of the liver (hepatitis) increased sensitivity of the skin to sunlight increased pressure in the brain changes in the number or type of certain blood cells pain in the upper part of the abdomen changes in some blood tests (tests of liver function) fever itchiness, skin rash or hives inflammation of the intestine depression nightmare The following side effects may occur during treatment with the class of medicines to which Tetralysal belongs (the tetracyclines): systemic lupus erythematosus (an allergic condition that causes joint pain, skin rashes or fever) inflammation or ulceration of the gullet, causing pain or difficulty swallowing or painful heartburn. difficulty in swallowing inflammation of the pancreas liver damage teeth discolouration inflammation or soreness of the tongue, mouth, cheeks, gums or lips soreness or itching of the genital area yeast infection around the anus or genitals infection of the colon * the presence of symptoms, such as visual disturbances, or headaches, could be attributed to increased pressure in the brain (intracranial hypertension). You should stop taking Tetralysal if there is any evidence of pressure increase in the brain. Benign intracranial hypertension, symptoms of which may incude headache, vomiting, visual disturbances (blurred vision, blind spots or double vision), or permanent visual loss have been reported with tetracycline therapy. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via www.mhra.gov. uklyellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. –
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Tetralysal Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month. Do not store above 25°C. Store in the original container. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
GALDERMA
Galderma
Colors
Product code: P23873-13 Product description: TETRALYSAL 300 Market: GBR Article: Leaflet Font size: 8 pt Flat size: 180×315 Fold size: 180×26,25 Pharmacode: 130 GRAPHIC DESIGNER: Guillaume DEPARTMENT -Z.l.
–
GALDERMA
PMS 432U
P23873-13
What Tetralysal contains The active substance is Iymecycline. Each capsule contains 408mg of Iymecycline. The other ingredients are magnesium stearate and colloidal hydrated silica. The capsule shells contain gelatin, titanium dioxide (E171), erythrosine (E127), quinoline yellow (E104) and indigotine (E132). What Tetralysal looks like and contents of the pack Tetralysal capsules are red and yellow. Tetralysal is available in a carton containing 28 or 56 capsules packed in polyethylene/foil blisters. Each blister strip contains 4 capsules and there are 7 or 14 blister strips in each carton. A carton containing 28 capsules in PVC/foil blisters (14 capsules in two calendar strips) is also approved. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Galderma (UK) Limited, Evergreen House North, Grafton Place, London, NW1 ZDX, United Kingdom (PL 10590/0019) Manufacturer: Laboratoires Sophartex, B.P. 129, 28501 Vernouillet, France or Laboratoires Galderma, ZI-Montdésir, 74540 Alby-sur-Chéran, France This leaflet was last revised in 04/2022.
Tetralysal 300mg Hard Capsules comes as capsule containing 300mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Tetralysal 300mg Hard Capsules is lymecycline.
This leaflet reproduces the patient information leaflet approved for Tetralysal 300mg Hard Capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Tetralysal is indicated for the treatment of infections caused by tetracycline sensitive organisms (please see section 4.4 and 5.1) including the following:
• Acne
• Ear, nose and throat infections
• Acute exacerbation of chronic bronchitis
• Gastro-intestinal infection
• Urinary tract infection
• Non-gonococcal urethritis
• Trachoma
• Rickettsial fever
• Soft tissue infection
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Adults:
The usual dosage for the chronic treatment of acne is 1 capsule daily (300 mg/day): treatment should be continued for at least 8 weeks.
For other infections, the usual dosage is 1 capsule b.d. (600 mg/day). If higher doses are required, 3-4 capsules (900-1200 mg) may be given over 24 hours. Lower doses may be given for prophylaxis.
In the management of sexually transmitted disease both partners should be treated.
Elderly:
As for other tetracyclines, no specific dose adjustment is required.
Paediatric population:
The safety and efficacy of Tetralysal in children aged under 12 years of age have not been established. No data are available.
For children over the age of 12 years, the adult dosage may be given.
For children under the age of 8 years, see section 4.3.
Methods of administration
The capsules should be taken with a glass of water in order to reduce the risk of oesophageal irritation and ulceration (see section Special warnings and precautions for use).
Hypersensitivity to the active substance or any other tetracycline or to any of the excipients listed in section 6.1.
Its use is contraindicated in patients with overt renal insufficiency and in children aged under 8 years due to the risk of permanent dental staining and enamel hypoplasia.
Concurrent treatment with oral retinoids (see Interaction with other Medications).
Oesophageal irritation and ulceration
Solid dosage forms of the tetracyclines may cause oesophageal irritation and ulceration. To avoid oesophageal irritation and ulceration, adequate fluids (water) should be taken with this medicinal product (see section Posology and method of administration).
Caution should be exercised if the product is administered to patients with impaired renal or hepatic functions.
Hepatotoxicity
Overdosage could result in hepatotoxicity
Antibiotic resistance
Prolonged use of broad spectrum antibiotics may result in the appearance of resistant organisms and superinfection.
Phototoxicity
Due to the risks of photosensitivity, it is recommended to avoid exposure to direct sunlight and ultraviolet light during the treatment which should be discontinued if erythematous cutaneous manifestations occur.
Expired medication
The use of expired tetracyclines can lead to renal tubular acidosis (Pseudo-Fanconi syndrome) readily reversible when treatment is discontinued altogether.
Systemic lupus erythematosus
May cause exacerbation of systemic lupus erythematosus.
Myasthenia Gravis
Can cause weak neuromuscular blockade so should be used with caution in Myasthenia Gravis.
Hepatic impairment
Care should be exercised when administering tetracyclines to patients with hepatic impairment.
Paediatric population
The product should not be used in children below 12 years of age due to the risk of permanent dental staining and enamel hypoplasia (see Contraindications).
Simultaneous administration of iron preparations and anti-acids, magnesium/aluminium and calcium hydroxides, oxides, salts, cholestyramine, bismuth chelates, sucralfate and quinapril may decrease cycline absorption. Enzyme inducers such as barbiturates, carbamazepine, phenytoin may accelerate the decomposition of tetracycline due to enzyme induction in the liver thereby decreasing its half-life. These products should not be taken within two hours before or after taking Tetralysal 300.
Some adverse effects are reported with tetracycline therapy in general in case of combination with lithium; an interaction between lithium and the tetracycline class is a recognised interaction. A combination of lymecycline with lithium may cause an increase in serum lithium levels.
Unlike earlier tetracyclines, absorption of Tetralysal 300 is not significantly impaired by moderate amounts of milk.
Concomitant use of oral retinoids and vitamin A (above 10 000 IU/day) should be avoided as this may increase the risk of benign intracranial hypertension. An increase in the effects of anticoagulants may occur with tetracyclines with an increased risk of haemorrhage. Concomitant use of diuretics should be avoided.
Bacteriostatic medicinal products including lymecycline may interfere with the bacteriocidal action of penicillin and beta-lactam antibiotics. It is advisable that tetracycline-class drugs and penicillin should not therefore be used in combination.
Tetracyclines and methoxyflurane used in combination have been reported to result in fatal renal toxicity.
Paediatric population
Interaction studies have only been performed in adults.
Tetracyclines are selectively absorbed by developing bones and teeth and may cause dental dyschromia and enamel hypoplasia (see section 4.3).
Pregnancy
Tetracyclines readily cross the placental barrier. Therefore, Tetralysal 300 should not be administered to pregnant women.
Breastfeeding
Tetracyclines are distributed into milk. Therefore, Tetralysal 300 should not be administered to breast-feeding women (risk of enamel hypoplasia or dental dyschromia in the infant) (see section 4.3).
Fertility
No data on the effect on fertility is available.
No studies on the effects on the ability to drive and use machines have been performed
Tabulated list of adverse reactions
The most frequently reported adverse events with Tetralysal are gastrointestinal disorders of nausea, abdominal pain, diarrhoea and nervous system disorder of headache. The most serious adverse events reported with Tetralysal are Stevens Johnson syndrome, anaphylactic reaction, angioneurotic oedema and intracranial hypertension.
System Organ Class
Frequency
Adverse Reaction
Blood and lymphatic system disorders
Unknown
Neutropenia
Thrombocytopenia
Eye disorders
Unknown
Visual disturbance*
Gastrointestinal disorders
Common
(≥1/100 and <1/10)
Nausea
Abdominal pain
Diarrhoea
Unknown
Epigastralgia
Glossitis
Vomiting
Enterocolitis
General disorders and administration site conditions
Unknown
Pyrexia
Hepatobiliary disorders
Unknown
Jaundice
Hepatitis
Immune system disorder
Unknown
Anaphylactic reaction
Hypersensitivity
Urticaria
Angioneurotic oedema
Investigations
Unknown
Transaminases increased
Blood alkaline phosphatase increased
Blood bilirubin increased
Nervous system disorders
Common
(≥1/100 and <1/10)
Headache
Unknown
Dizziness
Intracranial hypertension
Skin and subcutaneus tissues disorders
Unknown
Erythematous rash
Photosensitivity
Pruritus
Stevens Johnson syndrome
Psychiatric disorders
Unknown
Depression
Nightmare
Description of selected adverse reactions
*The manifestation of clinical symptoms, including vision disorders, or headache, must suggests the possibility of a cranial hypertension diagnosis. If increased intracranial pressure is suspected during treatment with Tetralysal, administration should be stopped.
Benign intracranial hypertension and bulging fontanelles in infants were reported with tetracyclines with possible symptoms of headaches, vomiting, visual disturbances including blurring of vision, scotomata, diplopia or permanent visual loss.
The following adverse effects were reported with tetracyclines in general and may occur with Tetralysal: dysphagia, oesophagitis, oesophageal ulceration, systemic lupus erythematosus, pancreatitis, teeth discolouration, hepatitis, hepatic failure. Dental dyschromia and/or enamel hypoplasia may occur if the product is administered in children younger than 8 years of age.
As with all antibiotics overgrowth of non susceptible organisms may cause candidiasis, pseudomembranous colitis (Clostridium Difficile overgrowth), glossitis, stomatitis, vaginitis or staphyloccocal enterocolitis.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Symptoms
Acute overdosage is rare with antibiotics and there is no specific treatment.
Management
Supportive measure should be instituted as required and a high fluid intake maintained.
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Tetralysal 300mg Hard Capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.